ARTICLE | Targets & Mechanisms
Gilding the Goldfinch
Why Third Rock is betting Goldfinch can bring innovation to kidney disease
February 17, 2017 1:00 AM UTC
In launching Goldfinch Biopharma Inc., Third Rock is extending its already heavy footprint in precision medicine into chronic kidney disease. The VC thinks the unfolding genetics in that field can yield disease-modifying therapies and a blueprint for finding the right patients.
Goldfinch was the fourth precision medicine newco in 2016 from Third Rock Ventures, and the 17th in its portfolio, but this is the firm’s first foray into kidney disease. Third Rock was the sole investor in the $55 million series A round in December that launched the company. ...
BCIQ Company Profiles